Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Beligere N, Perumalswamy V, Tandon M, Mittal A, Floora J, Vijayakumar B, et al. Retinopathy of prematurity and neurodevelopmental disabilities in premature infants. Semin Fetal Neonatal Med. 2015;20:346–53.
Goyen T-A, Todd DA, Veddovi M, Wright AL, Flaherty M, Kennedy J. Eye-hand co-ordination skills in very preterm infants <29 weeks gestation at 3 years: effects of preterm birth and retinopathy of prematurity. Early Hum Dev. 2006;82:739–45.
Allred EN, Capone A, Fraioli A, Dammann O, Droste P, Duker J, et al. Retinopathy of prematurity and brain damage in the very preterm newborn. J Aapos. 2014;18:241–7.
Msall ME, Phelps DL, DiGaudio KM, Dobson V, Tung B, McClead RE, et al. Severity of neonatal retinopathy of prematurity is predictive of neurodevelopmental functional outcome at age 5.5 years. Behalf of the Cryotherapy for Retinopathy of Prematurity Cooperative Group. Pediatrics. 2000;106:998–1005.
Todd DA, Goyen T-A, Smith J, Rochefort M. Developmental outcome in preterm infants <29 weeks gestation with ≤Stage 3 retinopathy of prematurity (ROP): relationship to severity of ROP. J Dev Orig Health Dis. 2012;3:116–22.
Funding
This work was supported by the Heed Ophthalmic Foundation and Michels Fellowship Foundation awarded to NFC, MD, MS.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
DMM has the following conflicts of interest: 1–800 Contacts (board of directors, equity), Akceso Advisors AG (evaluation of DME market), Akebia (scientific advisory board for ROP), Alcon (data safety monitoring board for HAWK/HARRIER), Aldeyra Therapeutics (Site PI: ADX-2191-PVR-001 GUARD), Allegro (scientific advisory board), Apellis (Site PI: APL2-303 DERBY), Bayer Pharma AG (ROP imaging committee), CMEOutfitters.com (CME consultant), Cole Eye Institute (CME consultant), Congruence medical solutions (consultant), dSentz, Inc. (founder, board of directors, equity), Genentech (PROPER grant 2019), Grand Legend Technology, LTD (equity), Iconic Therapeutics (steering committee, unpaid), Irenix (scientific advisory board, unpaid), Linc (founder, equity, board of directors), Northwell Health (grand rounds), Novartis Pharmaceuticals (data safety monitoring board for HAWK/HARRIER, KITE/KESTREL, China nAMD/DME, pediatric advisory board), Ocular Surgery News (consultant), Pr3vent (founder, board of directors, equity), Praxis UNS, Inc. (consultant), Prime Medical Education (CME consultant), Promisight, Inc. (founder, board of directors, equity), Pykus (scientific advisory board, equity), Regeneron (CME consultant, ROP steering committee, PI for ROP trial), Retina Technologies LLC (advisor, consultant), Retina Today/Pentavision (consultant), Shapiro Law Group (ROP expert witness), SLACK, Inc. (CME consultant), University of Miami (CME consultant), VersI, Inc. (founder, equity), Vindico (CME consultant), Visunex (scientific advisory board, equity). The remaining authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Al-Moujahed, A., Azad, A., Vail, D. et al. Retinopathy of prematurity and neurodevelopmental outcomes in premature infants. Eye 35, 1014–1016 (2021). https://doi.org/10.1038/s41433-020-0941-x
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41433-020-0941-x
